30results about How to "Target-specific" patented technology

The invention, relating to the technical field of medical use, particularly relates to a living molecular imaging method and a targeting molecular imaging probe. The living molecular imaging method is characterized by introducing the targeting molecular imaging probe capable of being detected by an imaging device to reflect biochemical change characteristics of connexin protein 43 (Cx43) of cardiovascular diseases (especially arrhythmia), tumor and the like in the form of images, and has accurate detection results. According to the invention, the distribution and amount of the Cx43 can be displayed visually, and the method can be directly applied to human body. The Cx43 targeting molecular imaging probe disclosed herein comprises a signal component, a Cx43 targeting compatible component and a connector, and has good pharmacokinetic characteristics and biological distribution characteristics.

The invention discloses a compound herbicide for preventing and removing ligularia virgaurea as well as a preparation method and an application method thereof. The compound herbicide is composed of the following raw materials in percentage by weight: 2%-40% of tribenuron-methyl, 5%-40% of clopyralid, 40%-90% of bentazone and the balance being auxiliary agents. The preparation method of the compound herbicide comprises the following steps: adding the tribenuron-methyl, the bentazone and the clopyralid, which are weighed according to the weight ratio, into an agitator; adding 5L-20L of tap water and agitating uniformly at a low speed; then adding sodium dodecyl benzene sulfonate, alkylphenol polyoxyethylene and polytrisiloxane according to the weight ratio; sufficiently agitating and uniformly mixing; and filling bottles and sealing. The application method of the compound herbicide comprises the step of spraying the compound herbicide on stems and leaves of ligularia virgaurea at a flowering period, wherein the herbicide spraying amount is 750-3000 g / hectare. The compound herbicide has high selectivity, special target and obvious prevention and removing effects on the specific plant, ligularia virgaurea, has a good ecological effect and can protect the biological diversity of grass lands very well.

The invention especially relates to a radioactive C-MET-targeted affinity micromolecular compound and application thereof, belonging to the field of medical diagnosis and treatment. According to the invention, in-vivo tracking and imaging of diseases like tumors is realized through radiolabeling of a C-MET receptor antagonist. The radioactive C-MET-targeted affinity micromolecular compound can be used for monitoring the characteristics of biochemical changes of a hepatocyte growth factor receptor, visually displays the distribution and quantity of C-MET and is applicable to specific detection of a plurality of cancers including glioma, lung cancer, prostatic cancer, breast cancer, esophagus cancer, stomach cancer, liver cancer, pancreas cancer, ovarian cancer, rectal cancer and cervical cancer. The radioactive C-MET-targeted affinity micromolecular compound also has certain anticancer activity and has wide clinical application prospect.

The invention relates to a vascular targeting embolism sustained release agent of a triple compound microsphere for an antituberculosis drug, a preparation method and applications thereof. The sustained release agent comprises a carrier and a drug, wherein the drug is encapsulated by the carrier, the carrier is selected from sodium alginate or chitosan, and the drug is a triple compound antituberculosis drug which comprises rifampin, isoniazide and pyrazinamide or moxifloxacin. Three antituberculosis drugs are employed as matrixes of a drug solution, sodium alginate or chitosan is used as a carrier solution, and a prepared solution is obtained by mixing the drug solution and the carrier solution. A polymer solution having the drug is enabled to be dispersed into droplets with certain particle sizes and to be sprayed into a curing liquid through a method of high voltage electrostatic droplets, and thus the microsphere for the antituberculosis drug are prepared in the presence of calcium ions. The embolism sustained release agent can be used in the drug for treating pulmonary tuberculosis, pulmonary tuberculosis massive hemoptysis, cavitary pulmonary tuberculosis, renal tuberculosis, osteoarticular tuberculosis, genital tubercolosis, thyroid tuberculosis, tuberculosis of cervical lymph nodes, pericardial tuberculosis, chest-wall tuberculosis and other in-vivo tuberculosises.

The invention provides a drug virtual screening system for crystal complexes, including a visualization subsystem, an evaluation toolbox system, an AI model management subsystem, a large-scale sampling subsystem, a virtual screening subsystem and a data log storage subsystem; Starting from the known crystal complexes, through the visualization subsystem, the evaluation toolbox system, the AI ​​model management subsystem, the large-scale sampling subsystem, and the virtual screening system, a batch of candidate compounds that meet the requirements are recommended. Based on this system, the generation of compound libraries is organically combined with subsequent virtual screening. Users can generate a batch of expected compounds as long as they describe the mode of action of the drug on the protein and the requirements that the drug needs to have. The automated system reduces user intervention and increases the efficiency of R&D.

The invention provides the application of a medicine or a product prepared by aptamer and used for treating multiple myeloma. The aptamer adopts TY04, and belongs to single strand DNA containing 83 basic groups. The action principle of the aptamer is that the aptamer can present cell specificity and sequence specificity and be stably combined with protide substances on the surface of multiple myeloma cells, operate the expression of related protein of cyclin B, CDK1, ERK1 / 2 and gamma-tubulin by lowering the cell cycle, and retard the process of multiple myeloma cell cycle to G2 / M phase, thereby restraining the multiplication of the multiple myeloma cells. Presently, the aptamer for treating multiple myeloma is not reported at home and abroad. The discovery and application of the aptamer can provide a novel strategy for treating multiple myeloma.

The invention belongs to the field of medical embolization devices, relates to a sodium alginate microsphere targeted vascular embolization agent containing an antineoplastic drug and a preparation method thereof. Alginic acid is taken as a pharmaceutical carrier, the antineoplastic drug etoposide is a pharmaceutical active ingredient, divalent metal cation or calcium ion solution is taken as a solidifying agent, and the sodium alginate encapsulates the etoposide to prepare ideal particle size-controllable sodium alginate microspheres comprising the etoposide, thus avoiding toxic side effect of traditional etoposide administration such as anaphylaxis and inconvenience. The vascular embolization agent changes the dosage form and route of administration way of the antineoplastic drug etoposide, has high efficacy and low toxicity, and is safely and effectively applied to clinical application. The vascular embolization agent has the advantages of mild preparation condition and simple and convenient operation, and is fit for large-scale production. The vascular embolization agent can be used for vascular embolization, local targeted tumor treatment, and treating small-cell carcinoma ofthe lung, oophoroma, carcinoma of testis, gastric cancer and liver cancer by administering the vascular embolization agent during operations.

The invention relates to a sodium alginate micro ball vessel suppository which contains soluble medicine, and relative preparation and application, wherein said agent can be divided into two kinds aswet ball and dry ball made from degradable biological material; said carrier comprises sodium alginate, blood serum albumin, chitose, or transparent sodium solution, via the static to be solidified with calcium ion, to be made into the micro ball at 20 mum-1000 mum. The inventive material has high mechanical strength, biological compatibility, biological degradability and stability. The inventioncan be used to cure the vessel suppository of variable cancers.

The invention provides a multivalent aptamer DNA nano-ladder and its preparation method and application. The present invention uses natural DNA molecules as raw materials, and on the basis of DNA origami theory, utilizes the special properties of rolling circle amplification products to construct a DNA nano-ladder, and introduces a large number of aptamers to construct a ladder with simple design and strong drug-loading capacity. , a drug delivery system with target specificity and biocompatibility, and through aptamer or drug replacement, the carrier can also be applied to various types of target cells.

The invention discloses a genetic micro-chain carrier, which comprises a linear DNA sequence expression cassette and two symmetrically arranged Cap protection sequences; wherein the Cap protection sequences close both ends of the linear DNA sequence expression cassette and are modified forming different protection structures, based by the building of MEKK1 micro-chain carrier specifically expressing inside the tumour relative with EB virus. The invention simultaneously discloses a construction method of the genetic micro-chain carrier. The invention has the advantages of good versatility of loading foreign gene and convenient replacement, since the linear nucleic acid structure of the micro-chain carrier comprises a replaceable target gene expression cassette; the chance to be a popular carrier of gene therapy, providing a new thinking and direction for the carrier development of gene therapy.

The invention relates to a triple compound microsphere vascular targeted embolization sustained-release preparation containing an antituberculous drug as well as a preparation method and application of the preparation. The sustained-release agent comprises a carrier and drugs, wherein the drugs are coated with the carrier; the carrier is sodium alginate or chitosan, and the drugs are triple antituberculous compound drugs including rifampicin, isoniazid and pyrazinamide or moxifloxacin. The three antituberculous drugs are matrix drug solutions, the sodium alginate or chitosan is a carrier solution, the matrix drug solutions and the carrier solutiona are mixed to prepare a solution, the polymer solution containing drugs is dispersed into fogdrops with a certain diameter by adopting a high-voltage electrostatic droplet mode, and the fogdrops are sprayed into a solidifying liquid to prepare antituberculous drug microspheres under the action of calcium ions. The embolization sustained-release preparation can be used for treating tuberculosis, massive hemoptysis of pulmonary tuberculosis, tuberculosis cavity, renal tuberculosis, osteoarticular tuberculosis, genital tuberculosis, tuberculosis of thyroid gland, tuberculosis of cervical lymph nodes, tuberculosis of pericardium, tuberculosis of chest wall, pleural tuberculosis and other kinds of tuberculosis in a body.